Therefore, the PD-L1 targeting of IL-15 differentiates KD033 treatment from ICIs, free IL-15, modified free IL-2, or immune-checkpoint inhibitor treatments, and highlights the merit of KD033’s testing in various cancer indications. Here, IL15 is linked to cancer.